Skip to main content
Figure 12 | Kinetoplastid Biology and Disease

Figure 12

From: Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006

Figure 12

Immuno-chemotherapy of persistent PKDL patients in Sudan. Double-blind randomized antimony alone controlled vs. immunochemotherapy trial of 30 persistent PKDL patients. All patients received the standard daily injections of Sodium Stibo-Gluconate (SSB) for 40 days. Patients were randomized to receive 4 weekly injections of alum-precipitated autoclaved L. major (alum-ALM) + one tenth of normal dose of BCG or a placebo (BCG diluent). On day 60, 87% in the combined immuno-chemotherapy group were cured and the rest improved vs. 53% in chemotherapy alone group cured and the rest failed (efficacy = 72%, 95% CI: 0.8–1.18). By day 90 all patients in immunochemotherapy had cured vs. Adopted from Musa, A. & Khalil, EAG, et al.)

Back to article page

Kinetoplastid Biology and Disease

ISSN: 1475-9292